Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMRQAM0)

Drug Name
Phenacetin Drug Info
Synonyms
phenacetin; 62-44-2; Acetophenetidin; N-(4-Ethoxyphenyl)acetamide; Acetphenetidin; Acetophenetidine; Acetophenetin; Phenacetine; p-Acetophenetidide; Contradouleur; Commotional; Achrocidin; Phenazetin; Contradol; Codempiral; 4'-Ethoxyacetanilide; 4-Ethoxyacetanilide; Acetamide, N-(4-ethoxyphenyl)-; p-Acetophenetidine; Fenacetina; Phenidin; Pyraphen; Phenacitin; Phenacetinum; Fenidina; Phenedina; Phenacet; Pertonal; Fenina; Phenin; Kalmin; p-Acetphenetidin; p-Acetophenetide; Phenazetina; Tetracydin; p-Ethoxyacetanilide; Stellacyl; Phenodyne; Imidazo[4,5-e][1,4]diazapine nucleotide (I)
Indication
Disease Entry ICD 11 Status REF
Analgesia MB40.8 Withdrawn from market [1]
Cross-matching ID
PubChem CID
4754
ChEBI ID
CHEBI:8050
CAS Number
CAS 62-44-2
TTD Drug ID
DMRQAM0
VARIDT Drug ID
DR00653
INTEDE Drug ID
DR1270

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) TTL7C8Q IMDH1_HUMAN Inhibitor [2]
Prostaglandin G/H synthase 1 (COX-1) TT8NGED PGH1_HUMAN Inhibitor [3]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID Highest Status REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Phase 4 [4]
Cytochrome P450 2E1 (CYP2E1) DEVDYN7 CP2E1_HUMAN Phase 4 [4]
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Phase 4 [5]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Phase 4 [6]
Cytochrome P450 1A1 (CYP1A1) DE6OQ3W CP1A1_HUMAN Phase 4 [7]
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Phase 4 [6]
Cytochrome P450 2A6 (CYP2A6) DEJVYAZ CP2A6_HUMAN Phase 4 [6]
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Phase 4 [8]
Cytochrome P450 2A13 (CYP2A13) DEXZA9U CP2AD_HUMAN Phase 4 [8]
Cholesterol 24-hydroxylase (CYP46A1) DEKP5HX CP46A_HUMAN Phase 4 [9]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Prostaglandin G/H synthase 1 (COX-1) DTT PTGS1 6.09 7.747 6.04 7.023
Cytochrome P450 2A13 (CYP2A13) DME CYP2A13 3.485 1.07 3.278 2.459
Cytochrome P450 2E1 (CYP2E1) DME CYP2E1 12.054 3.968 2.945 4.1
Cholesterol 24-hydroxylase (CYP46A1) DME CYP46A1 5.361 4.062 4.087 5.966
Cytochrome P450 2A6 (CYP2A6) DME CYP2A6 10.644 6.631 6.598 6.937
Cytochrome P450 1A2 (CYP1A2) DME CYP1A2 10.036 5.779 6.508 6.481
Mephenytoin 4-hydroxylase (CYP2C19) DME CYP2C19 7.867 5.142 5.52 7.08
Cytochrome P450 2D6 (CYP2D6) DME CYP2D6 3.307 5.005 3.921 5.327
Cytochrome P450 1A1 (CYP1A1) DME CYP1A1 5.952 6.384 4.897 6.293
Cytochrome P450 2C9 (CYP2C9) DME CYP2C9 11.76 5.931 6.164 9.423
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 11.692 6.58 4.984 9.089
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Analgesia
ICD Disease Classification MB40.8
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Prostaglandin G/H synthase 1 (COX-1) DTT PTGS1 3.97E-03 0.16 0.43
Cytochrome P450 2A13 (CYP2A13) DME CYP2A13 9.89E-01 -6.41E-03 -3.83E-02
Cytochrome P450 2E1 (CYP2E1) DME CYP2E1 1.87E-04 -1.20E-01 -3.22E-01
Cholesterol 24-hydroxylase (CYP46A1) DME CYP46A1 1.79E-06 -3.32E-01 -6.53E-01
Cytochrome P450 2A6 (CYP2A6) DME CYP2A6 2.02E-01 -2.49E-02 -1.81E-01
Cytochrome P450 1A2 (CYP1A2) DME CYP1A2 7.36E-01 1.62E-02 1.08E-01
Mephenytoin 4-hydroxylase (CYP2C19) DME CYP2C19 2.40E-01 -3.31E-02 -1.97E-01
Cytochrome P450 2D6 (CYP2D6) DME CYP2D6 7.30E-01 -1.91E-02 -1.41E-01
Cytochrome P450 1A1 (CYP1A1) DME CYP1A1 6.83E-06 -1.42E-01 -4.93E-01
Cytochrome P450 2C9 (CYP2C9) DME CYP2C9 1.90E-01 -9.81E-03 -5.96E-02
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 1.04E-02 6.29E-02 3.54E-01
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7402).
2 A potent "fat base" nucleotide inhibitor of IMP dehydrogenase. Biochemistry. 1998 Aug 25;37(34):11949-52.
3 Direct toxicity of nonsteroidal antiinflammatory drugs for renal medullary cells. Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5317-22.
4 Involvement of CYP2E1 as A low-affinity enzyme in phenacetin O-deethylation in human liver microsomes. Drug Metab Dispos. 1999 Aug;27(8):860-5.
5 Human cytochromes P450 mediating phenacetin O-deethylation in vitro: validation of the high affinity component as an index of CYP1A2 activity. J Pharm Sci. 1998 Dec;87(12):1502-7.
6 Activation of phenacetin O-deethylase activity by alpha-naphthoflavone in human liver microsomes. Xenobiotica. 1999 Sep;29(9):885-98.
7 Identification of CYP3A4 as the enzyme involved in the mono-N-dealkylation of disopyramide enantiomers in humans. Drug Metab Dispos. 2000 Aug;28(8):937-44.
8 CYP2A13 metabolizes the substrates of human CYP1A2, phenacetin, and theophylline. Drug Metab Dispos. 2007 Mar;35(3):335-9.
9 Broad substrate specificity of human cytochrome P450 46A1 which initiates cholesterol degradation in the brain. Biochemistry. 2003 Dec 9;42(48):14284-92.